Latest news
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeatMarketBeat · Sat, 08 Aug 2026 00:16:46 GMT[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock TitanStock Titan · Thu, 06 Aug 2026 20:37:53 GMTSpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 20:37:00 GMTSpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - tradingview.comtradingview.com · Thu, 06 Aug 2026 20:35:16 GMTSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:05:00 GMTSpyGlass glaucoma trial enrollment remains on track for 2027 - Stock TitanStock Titan · Thu, 06 Aug 2026 20:05:00 GMT